New drug cocktail aims to wipe out rare, aggressive breast cancer before surgery

NCT ID NCT05795101

Recruiting now Disease control Sponsor: Filipa Lynce, MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase II trial is testing whether combining two drugs—trastuzumab deruxtecan (Enhertu) and durvalumab—given before surgery can eliminate cancer in people with stage III inflammatory breast cancer that has HER2 protein. The study will enroll 63 participants and measure how many have no cancer left at the time of surgery. The goal is to find a more effective pre-surgery treatment for this rare and fast-growing cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab deruxtecan (Enhertu) and durvalumab
What this could lead to: If successful, this combination could offer a new treatment option before surgery for people with a rare and aggressive form of breast cancer, potentially improving the chance of eliminating all cancer cells.
What could go wrong: This is a small, early-phase study (63 people) with no control group, so results may not apply broadly. The drugs can cause serious side effects like lung inflammation or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast adenocarcinoma breast cancer breast neoplasm HER2 positive breast carcinoma inflammatory breast carcinoma invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HER2 LOW BREAST ADENOCARCINOMA HER2-POSITIVE BREAST CANCER INFLAMMATORY BREAST CANCER STAGE III INVASIVE BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Phone: •••-•••-••••

Contact
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.